Literature DB >> 15527695

Evolution of diagnostic criteria for primary aldosteronism: why is it more common in "drug-resistant" hypertension today?

Clarence E Grim1.   

Abstract

The recent "epidemic" of primary aldosteronism reported in the literature is most likely related to the widespread acceptance that with easy access to accurate measurements of renin and aldosterone, it is no longer necessary to wait until hypokalemia has become profound before embarking on diagnostic testing to attempt to ferret out this most common cause of "essential" hypertension. This is especially true for those who are now classified as "drug resistant" using today's popular drugs, which are particularly ineffective in lowering blood pressure in primary aldosteronism and its variants. Understanding the physiologic consequences of a slowly increasing aldosterone production by autonomous cells will help both the family practitioner and the specialist understand the role of the aldosterone renin ratio (ARR) in the care of the hypertensive patient. In addition, the increasing number of specific genetic mutations that drive sodium retention and lead to low levels of renin activity and familial hypertension must be incorporated into the routine evaluation and care of hypertensive patients and their families.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15527695     DOI: 10.1007/s11906-004-0045-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  36 in total

1.  Liddle's syndrome: prospective genetic screening and suppressed aldosterone secretion in an extended kindred.

Authors:  J W Findling; H Raff; J H Hansson; R P Lifton
Journal:  J Clin Endocrinol Metab       Date:  1997-04       Impact factor: 5.958

2.  Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension.

Authors:  A C Guyton; T G Coleman; A V Cowley; K W Scheel; R D Manning; R A Norman
Journal:  Am J Med       Date:  1972-05       Impact factor: 4.965

3.  Suppression of renin and aldosterone by small amounts of DOCA in normal man.

Authors:  R E Shade; C E Grim
Journal:  J Clin Endocrinol Metab       Date:  1975-04       Impact factor: 5.958

Review 4.  A genetic defect resulting in mild low-renin hypertension.

Authors:  R C Wilson; S Dave-Sharma; J Q Wei; V R Obeyesekere; K Li; P Ferrari; Z S Krozowski; C H Shackleton; L Bradlow; T Wiens; M I New
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

5.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

Review 6.  Hypertension and the cortisol-cortisone shuttle.

Authors:  Marcus Quinkler; Paul M Stewart
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

7.  Diagnosis of secondary forms of hypertension. A comprehensive protocol.

Authors:  C E Grim; M H Weinberger; J T Higgins; N J Kramer
Journal:  JAMA       Date:  1977-03-28       Impact factor: 56.272

Review 8.  The current epidemic of primary aldosteronism: causes and consequences.

Authors:  Norman M Kaplan
Journal:  J Hypertens       Date:  2004-05       Impact factor: 4.844

9.  Abnormally sustained aldosterone secretion during salt loading in patients with various forms of benign hypertension; relation to plasma renin activity.

Authors:  R D Collins; M H Weinberger; A J Dowdy; G W Nokes; C M Gonzales; J A Luetscher
Journal:  J Clin Invest       Date:  1970-07       Impact factor: 14.808

10.  Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study.

Authors:  Takao Saruta; Shigeru Kageyama; Toshio Ogihara; Kunio Hiwada; Masayo Ogawa; Kazuji Tawara; Marjorie Gatlin; Susan Garthwaite; Richard Bittman; Jeffrey Patrick
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

View more
  8 in total

Review 1.  Treatment of resistant hypertension.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

2.  Familial mineralocorticoid induced hypertension in the sultanate of oman.

Authors:  Nicholas Jy Woodhouse; Omayma T Elshafie; Fatma Ben Abid; Suhail A Doi
Journal:  Sultan Qaboos Univ Med J       Date:  2008-07

3.  Resistant hypertension and undiagnosed primary hyperaldosteronism detected by use of a computerized database.

Authors:  Emmeline A Garcia; Julio R Lopez; Joy L Meier; Arthur L M Swislocki; David Siegel
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-03-28       Impact factor: 3.738

Review 4.  Individualizing antihypertensive combination therapies: clinical and hemodynamic considerations.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

Review 5.  Primary aldosteronism: diagnosis and treatment.

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

6.  The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study.

Authors:  Jenifer M Brown; Mohammed Siddiqui; David A Calhoun; Robert M Carey; Paul N Hopkins; Gordon H Williams; Anand Vaidya
Journal:  Ann Intern Med       Date:  2020-05-26       Impact factor: 25.391

7.  Clinical approach in treatment of resistant hypertension.

Authors:  Jennifer Frank; David Sommerfeld
Journal:  Integr Blood Press Control       Date:  2009-07-30

8.  Urotensin II Exerts Pressor Effects By Stimulating Renin And Aldosterone Synthase Gene Expression.

Authors:  Brasilina Caroccia; Mirko Menegolo; Teresa M Seccia; Lucia Petrelli; Michele Antonello; Alice Limena; Andrea Porzionato; Raffaele De Caro; Marko Poglitsch; Gian Paolo Rossi
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.